Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2020-08-06 Regulatory Filings
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes the termination of material definitive agreements and a press release announcing financial results for the quarter ended June 30, 2020. The document explicitly states that the press release is furnished and not filed, and the financial results announcement is a press release rather than a full earnings report. The document does not contain detailed financial statements or substantive financial data itself, but rather announces events and provides a link to a press release. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories like Earnings Release or Interim Report.
2020-08-06 English
FORM 4 -
Director's Dealing
2020-07-17 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 23, 2020, for Editas Medicine, Inc. It reports the entry into a material definitive agreement related to an underwritten public offering of common stock. The document includes details about the underwriting agreement, offering price, number of shares, and related exhibits such as the underwriting agreement and legal opinions. There are no financial statements or comprehensive financial data presented, only an announcement of a financing event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories. The document length is 5648 characters, which is sufficient to contain substantive information about the financing event itself, not just a brief announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2020-06-25 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) related to a public offering of common stock by Editas Medicine, Inc. It includes details such as the number of shares offered, pricing, underwriting discounts, use of proceeds, risk factors, and legal matters. The document is not a financial report, earnings release, or management discussion but rather a detailed offering document for capital raising. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, confirming it is not a Report Publication Announcement or Regulatory Filing. Therefore, the correct classification is CAP with high confidence.
2020-06-25 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3ASR registration statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes a preliminary prospectus for a public offering of common stock by Editas Medicine, Inc. The text references registration numbers, offering details, underwriters, and disclaimers typical of securities registration and offering documents. This is not a financial report, earnings release, or management discussion, but rather a capital raising filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2020-06-23 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 10, 2020, reporting the submission of matters to a vote of security holders at the company's Annual Meeting of Stockholders. It details the voting results for director elections, advisory vote on executive compensation, and ratification of the independent auditor. The content focuses on the official results of shareholder votes at the AGM, which aligns with the category 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 4317 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA.
2020-06-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.